Sera Prognostics Inc (SERA)vsStryker Corporation (SYK)
SERA
Sera Prognostics Inc
$2.03
+11.54%
HEALTHCARE · Cap: $70.82M
SYK
Stryker Corporation
$327.65
-0.26%
HEALTHCARE · Cap: $125.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 31007307% more annual revenue ($25.12B vs $81,000). SYK leads profitability with a 12.9% profit margin vs 0.0%. SYK earns a higher WallStSmart Score of 65/100 (C+).
SERA
Avoid27
out of 100
Grade: F
SYK
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for SERA.
Margin of Safety
+16.8%
Fair Value
$393.59
Current Price
$327.65
$65.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : SERA
The strongest argument for SERA centers on Price/Book, Debt/Equity.
Bull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bear Case : SERA
The primary concerns for SERA are EPS Growth, Market Cap, Profit Margin.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
SERA carries more volatility with a beta of 1.02 — expect wider price swings.
SYK is growing revenue faster at 11.4% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SYK scores higher overall (65/100 vs 27/100) and 11.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Sera Prognostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sera Prognostics Inc. is a pioneering healthcare company focused on advancing maternal-fetal health through innovative diagnostic solutions. Leveraging its proprietary biomarker platform, Sera developed the PreTRM test to assess the risk of preterm birth, enabling timely clinical interventions that can significantly improve pregnancy outcomes. With a strong emphasis on collaboration with healthcare providers, Sera is poised to lead the prenatal diagnostics market, enhancing both maternal health and overall societal well-being. The company's dedication to innovation not only aims to foster healthier pregnancies but also seeks to generate long-term value for its investors.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?